Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in previously untreated epithelial ovarian cancer
NCT02718417Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2016
- Primary completion
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of avelumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival as Assessed by Blinded Independent Central Review at 27 months. Started May 2016; status: terminated.
02
Drugs
avelumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02718417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718417.